Bernard A. Fox, Co-founder, President, and CEO of UbiVac, shared a post on LinkedIn:
“Prof. Chrystal Paulos cancer immunologist Rockstar at Emory University School of Medicine and a recipient of this year’s Melanoma Foundation award gives major lecture on their new TH17 TIL ( PolarTIL) that they are moving to the clinic!
Preclinical data shows these PolarTIL are much more therapeutic and drive Ab responses against the tumor. They also show that Ab plays a role in the improved therapeutic efficacy.
Dr. Paulos and her colleague / ‘intellectual tennis partner’ Gregory Lesinski – A truly Dynamic Duo.”
More posts featuring Bernard A. Fox.
